SciSparc (SPRC) Total Current Liabilities (2016 - 2025)
SciSparc (SPRC) posted Total Current Liabilities of $2.3 million for Q4 2025, down 55.28% sequentially from $5.0 million in Q2 2025, and up 61.04% YoY from $1.4 million in Q4 2024.
SciSparc (SPRC) Total Current Liabilities (2016 - 2025) Analysis & Trends
SciSparc has reported Total Current Liabilities for 10 years, with the latest figure at $2.3 million in Q4 2025.
- Quarterly Total Current Liabilities rose 61.04% year-over-year to $2.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.3 million (up 61.04% YoY) and the FY2025 annual result came in at $2.3 million, up 61.04% from the prior year.
- Total Current Liabilities slipped to $2.3 million in Q4 2025 per SPRC's latest filing, from $5.0 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $11.4 million in Q2 2022 and troughed at $754000.0 in Q2 2021.
- A 5-year average of $3.3 million and a median of $2.0 million in 2024 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2022 and 2023: Total Current Liabilities soared 1409.95% in 2022, then sank 72.65% in 2023.
- Over 5 years, Total Current Liabilities stood at $1.8 million in 2021, then soared by 136.54% to $4.2 million in 2022, then tumbled by 62.2% to $1.6 million in 2023, then fell by 10.95% to $1.4 million in 2024, then surged by 61.04% to $2.3 million in 2025.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $2.3 million, $5.0 million, and $1.4 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.92 Bn | 53.78 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.07 Bn | 36.97 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.70 Bn | 28.39 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 27.99 Bn | 9.60 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 630.93 Mn |
| 10 | SciSparc | 807,202.50 | 807,202.50 | - | 2.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.25 Mn |
| Jun 30, 2025 | 5.04 Mn |
| Dec 31, 2024 | 1.40 Mn |
| Jun 30, 2024 | 1.80 Mn |
| Dec 31, 2023 | 1.57 Mn |
| Jun 30, 2023 | 3.11 Mn |
| Dec 31, 2022 | 4.16 Mn |
| Jun 30, 2022 | 11.39 Mn |
| Dec 31, 2021 | 1.76 Mn |
| Jun 30, 2021 | 754,000.00 |
| Dec 31, 2020 | 1.13 Mn |
| Jun 30, 2020 | 1.64 Mn |
| Dec 31, 2019 | 1.05 Mn |
| Jun 30, 2019 | 2.22 Mn |
| Dec 31, 2018 | 4.48 Mn |
| Jun 30, 2018 | 1.23 Mn |
| Dec 31, 2017 | 1.18 Mn |
| Jun 30, 2017 | 671,000.00 |
| Dec 31, 2016 | 672,000.00 |